Sincalide: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 16:17, 1 February 2011 editLouisajb (talk \| contribs)Extended confirmed users4,402 edits added chemblid← Previous edit		Latest revision as of 09:29, 13 November 2024 edit undoCbare (talk \| contribs)104 editsm Add DrugBank accession
(31 intermediate revisions by 17 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
	{{drugbox
			{{one source\|date=October 2014}}
⚫	\| IUPAC_name = α-aspartyl-''O''-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
			{{Drugbox
⚫	\| image = Sincalide.svg
			\| Verifiedfields = changed
⚫	\| CAS_number = 25126-32-3
			\| Watchedfields = changed
⚫	\| ATC_prefix = V04
			\| verifiedrevid = 408748961
⚫	\| ATC_suffix = CC03
		⚫	\| IUPAC_name = α-aspartyl-''O''-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
⚫	\| PubChem = 32800
		⚫	\| image = Sincalide.svg
⚫	\| DrugBank =

⚫	\| ChEMBL_Ref = {{ebicite\|~~correct~~\|EBI}}
			<!--Clinical data-->
⚫	\| ChEMBL = 1121
	\| ~~KEGG~~ = ~~D05845~~		\| tradename =
			\| Drugs.com = {{drugs.com\|CONS\|sincalide}}
⚫	\| C=49\|H=62\|N=10\|O=16\|S=3
		⚫	\| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
	\| molecular_weight = 1143.27 g/mol
		⚫	\| pregnancy_US = B
⚫	\| synonyms = <small>1-De(5-oxo-L-proline)-2-de-L-glutamine-<br>5-L-methioninecaerulein, <nowiki>3--3-(4-sulfooxyphenyl)propanoyl]amino]-4-<br>methylsulfanyl-butanoyl]amino]acetyl]amino]-3-<br>(1''H''-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-<br>butanoyl]amino]-3-propanoic acid</small>
		⚫	\| pregnancy_category =
⚫	\| bioavailability =
		⚫	\| legal_AU = <!-- Unscheduled, S2, S3, S4, S5, S6, S7, S8, S9 -->
⚫	\| protein_bound =
		⚫	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	\| metabolism =
			\| legal_UK_comment = Available on a named-patient basis <!-- GSL, P, POM, CD, Class A, B, C -->
⚫	\| elimination_half-life =
		⚫	\| legal_US = Rx-only
⚫	\| excretion =
			\| legal_status =
⚫	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	\| pregnancy_US = B
⚫	\| pregnancy_category=
⚫	\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫	\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫	\| legal_US = Rx-only
	\| legal_status = Available on a named-patient basis <small>(])</small>
	\| routes_of_administration = ]		\| routes_of_administration = ]

			<!--Pharmacokinetic data-->
		⚫	\| bioavailability =
		⚫	\| protein_bound =
		⚫	\| metabolism =
		⚫	\| elimination_half-life =
		⚫	\| excretion =

			<!--Identifiers-->
			\| CAS_number_Ref = {{cascite\|correct\|??}}
		⚫	\| CAS_number = 25126-32-3
		⚫	\| ATC_prefix = V04
		⚫	\| ATC_suffix = CC03
		⚫	\| PubChem = 32800
			\| IUPHAR_ligand = 864
			\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
		⚫	\| DrugBank = DB09142
			\| UNII_Ref = {{fdacite\|changed\|FDA}}
			\| UNII = M03GIQ7Z6P
			\| KEGG_Ref = {{keggcite\|correct\|kegg}}
			\| KEGG = D05845
		⚫	\| ChEMBL_Ref = {{ebicite\|changed\|EBI}}
		⚫	\| ChEMBL = 1121
			\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
			\| ChemSpiderID = 8009168



			<!--Chemical data-->
		⚫	\| C=49 \| H=62 \| N=10 \| O=16 \| S=3
		⚫	\| synonyms = <small>1-De(5-oxo-L-proline)-2-de-L-glutamine-<br>5-L-methioninecaerulein, <nowiki>3--3-(4-sulfooxyphenyl)propanoyl]amino]-4-<br>methylsulfanyl-butanoyl]amino]acetyl]amino]-3-<br>(1''H''-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-<br>butanoyl]amino]-3-propanoic acid</small>
			\| smiles = CSCC(C(=O)NCC(=O)N(CC1=CNC2=CC=CC=C21)C(=O)N(CCSC)C(=O)N(CC(=O)O)C(=O)N(CC3=CC=CC=C3)C(=O)N)NC(=O)(CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)(CC(=O)O)N
			\| StdInChI_Ref = {{stdinchicite\|changed\|chemspider}}
			\| StdInChI = 1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
			\| StdInChIKey_Ref = {{stdinchicite\|changed\|chemspider}}
			\| StdInChIKey = IZTQOLKUZKXIRV-YRVFCXMDSA-N
	}}		}}
	'''Sincalide''' (]) is a ] drug administered by ] to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid ] fragment of ], and also known as '''CCK-8'''.		'''Sincalide''' (]) is a ] drug administered by ] to aid in diagnosing disorders of the ] and ]. It is the 8-amino acid ] fragment of ], and also known as '''CCK-8'''.

	Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.		Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

			==Clinical Use==

			===Indications===
			Sincalide may be used to stimulate ] contraction, as may be assessed by ] ] or ], or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, ]s, phospholipids, and crystals.<ref name="Ziessman_2019">{{cite journal \| vauthors = Ziessman HA \| title = Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues \| journal = Journal of Nuclear Medicine Technology \| volume = 47 \| issue = 3 \| pages = 210–212 \| date = September 2019 \| pmid = 31019045 \| doi = 10.2967/jnmt.119.226019 \| s2cid = 131775567 \| doi-access = free }}</ref> It can also be used to stimulate pancreatic secretion (especially in conjunction with ]) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and ]. In some instances it is used to accelerate the transit of a ] through the small bowel, thereby decreasing the time and-extent of radiation associated with ] and x-ray examination of the intestinal tract.<ref>Kinevac Package Insert</ref>

			==References==
			{{reflist}}

	==External links==		==External links==
	* ~~on ~~NIH~~.~~gov~~~~		* {{cite web \| url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7f3d501-a389-4fe1-b20a-c9665b3f3d37 \| title = KINEVAC (sincalide)] \| work = DailyMed \| publisher = U.S. National Library of Medicine }}


⚫	{{drug-stub}}
	{{Diagnostic agents}}		{{Diagnostic agents}}

	]		]
			]


		⚫	{{drug-stub}}

Latest revision as of 09:29, 13 November 2024

Chemical compound

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.
Find sources: "Sincalide" – news · newspapers · books · scholar · JSTOR (October 2014)

Pharmaceutical compound

Sincalide
Clinical data

Other names	1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3--3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-propanoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Intravenous
ATC code	V04CC03 (WHO)
Legal status
Legal status	UK: Available on a named-patient basis US: ℞-only
Identifiers
IUPAC name α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
CAS Number	25126-32-3
PubChem CID	32800
IUPHAR/BPS	864
DrugBank	DB09142
ChemSpider	8009168
UNII	M03GIQ7Z6P
KEGG	D05845
ChEMBL	ChEMBL1121
CompTox Dashboard (EPA)	DTXSID7048617
ECHA InfoCard	100.042.384
Chemical and physical data
Formula	C₄₉H₆₂N₁₀O₁₆S₃
Molar mass	1143.27 g·mol
3D model (JSmol)	Interactive image
SMILES CSCC(C(=O)NCC(=O)N(CC1=CNC2=CC=CC=C21)C(=O)N(CCSC)C(=O)N(CC(=O)O)C(=O)N(CC3=CC=CC=C3)C(=O)N)NC(=O)(CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)(CC(=O)O)N
InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N
(what is this?) (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.

References

Ziessman HA (September 2019). "Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues". Journal of Nuclear Medicine Technology. 47 (3): 210–212. doi:10.2967/jnmt.119.226019. PMID 31019045. S2CID 131775567.
Kinevac Package Insert

External links

"KINEVAC (sincalide)]". DailyMed. U.S. National Library of Medicine.

Diagnostic agents (V04)

Digestive system

Diabetes	Glucose Tolbutamide
Fat absorption	Vitamin A concentrates
Bile duct patency	Ceruletide Magnesium sulfate Sincalide Sorbitol
Liver functional capacity	Galactose Sulfobromophthalein
Gastric secretion	Betazole Caffeine and sodium benzoate Cation exchange resins Histamine phosphate Methylthioninium chloride Pentagastrin
Exocrine pancreatic function	Bentiromide Pancreozymin cholecystokinin Secretin

Endocrine system

Pituitary function	cortisol Corticorelin Metyrapone GH Pralmorelin Sermorelin Somatorelin
Thyroid function	Protirelin Thyrotropin
Fertility disturbances	Gonadorelin

Tuberculosis

Tuberculin

Renal function

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: